455 related articles for article (PubMed ID: 29490940)
1. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
Cabrera-Galeana P; Muñoz-Montaño W; Lara-Medina F; Alvarado-Miranda A; Pérez-Sánchez V; Villarreal-Garza C; Quintero RM; Porras-Reyes F; Bargallo-Rocha E; Del Carmen I; Mohar A; Arrieta O
Oncologist; 2018 Jun; 23(6):670-678. PubMed ID: 29490940
[TBL] [Abstract][Full Text] [Related]
2. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
3. HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer.
Fang Y; Zhang Q; Wu Y; Wu J
Medicine (Baltimore); 2024 Feb; 103(6):e37170. PubMed ID: 38335419
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
[TBL] [Abstract][Full Text] [Related]
7. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
8. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
9. Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer.
Tokuda E; Horimoto Y; Arakawa A; Himuro T; Senuma K; Nakai K; Saito M
Hum Pathol; 2017 May; 63():40-45. PubMed ID: 28237784
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
[TBL] [Abstract][Full Text] [Related]
11. Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy.
Tan S; Fu X; Xu S; Qiu P; Lv Z; Xu Y; Zhang Q
Pathol Oncol Res; 2021; 27():1609972. PubMed ID: 34987312
[No Abstract] [Full Text] [Related]
12. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
[TBL] [Abstract][Full Text] [Related]
13. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
14. Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population.
Wang J; Sang D; Xu B; Yuan P; Ma F; Luo Y; Li Q; Zhang P; Cai R; Fan Y; Chen S; Li Q
Medicine (Baltimore); 2016 May; 95(18):e3518. PubMed ID: 27149453
[TBL] [Abstract][Full Text] [Related]
15. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer.
Horimoto Y; Arakawa A; Tanabe M; Sonoue H; Igari F; Senuma K; Tokuda E; Shimizu H; Kosaka T; Saito M
BMC Cancer; 2014 Jul; 14():550. PubMed ID: 25073969
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H
Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496
[TBL] [Abstract][Full Text] [Related]
17. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
[TBL] [Abstract][Full Text] [Related]
18. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
[TBL] [Abstract][Full Text] [Related]
19. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
20. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
